Endocrine Society Explores Side Effects of Stopping and Restarting GLP-1 Drugs
Sunday, 14 June 2026, 14:08
Endocrine Society Research Findings
The Endocrine Society has published crucial research on the side effects of GLP-1 drugs, focusing on Ozempic and Wegovy. Recent studies indicate that discontinuing and later resuming these medications may lead to critical health considerations. The Journal of Clinical Investigation Insight outlines how these actions could affect patient outcomes.
Understanding GLP-1 Drug Use
- GLP-1 medications are commonly prescribed for weight management and diabetes.
- Stopping treatment can lead to weight regain and metabolic challenges.
- Careful management is essential in creating effective treatment plans.
Implications for Patients
Given the findings from the Endocrine Society, it is essential for healthcare professionals to communicate the potential consequences of stopping and restarting GLP-1 drugs.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.